Moffitt Cancer Center Logo
 

Jingsong Zhang, MD, PhD

Where You Are:

Jingsong Zhang, MD, PhD

Medical Oncology

For Consultation Requests or Referrals: (813) 745-8418

 
 

BOARD CERTIFICATION:
          •  Medical Oncology

FELLOWSHIP:
          •  University of Michigan Comprehensive Cancer Center - Hematology-Oncology

RESIDENCY:
          •  New York Downtown Hospital - Internal Medicine

MEDICAL SCHOOL:
          •  Peking Union Medical College - MD

  • Wu M, Wang X, McGregor N, Pienta K, Zhang J. Dynamic Regulation of Rad51 by E2F1 and p53 in Prostate Cancer Cells upon DrugInduced DNA Damage under Hypoxia. Mol Pharmacol. 2014 Mar. Pubmedid: 24627085.

  • Zhang J. Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer. Asian J Androl. 2014 Feb. Pubmedid: 24589464.

  • Liu JJ, Zhang J. Sequencing systemic therapies in metastatic castration-resistant prostate cancer. Cancer Control. 2013 Jul;20(3):181-187. Pubmedid: 23811702.

  • Song Y, Lucas M, Alcaraz M, Zhang J, Brazier C. Ultraviolet photodissociation dynamics of the phenyl radical. J Chem Phys. 2012 Jan;136(4):044308. Pubmedid: 22299872.

  • Zhang J, Lee J, Urba S, Foster J, Worden F. A phase II trial evaluating weekly docetaxel and capecitabine in patients with metastatic or advanced, locally recurrent head and neck cancers. Cancer Invest. 2010 Nov;28(9):910-916. Pubmedid: 20590443.

  • Kang HG, Jenabi JM, Zhang J, Keshelava N, Shimada H, May WA, Ng T, Reynolds CP, Triche TJ, Sorensen PH. E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res. 2007 Apr;67(7):3094-3105. Pubmedid: 17409416. Pmcid: PMC3906735.

  • Hu-Lieskovan S, Zhang J, Wu L, Shimada H, Schofield DE, Triche TJ. EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. Cancer Res. 2005 Jun;65(11):4633-4644. Pubmedid: 15930281.

  • Zhang J, Hu S, Schofield DE, Sorensen PH, Triche TJ. Selective usage of D-Type cyclins by Ewing's tumors and rhabdomyosarcomas. Cancer Res. 2004 Sep;64(17):6026-6034. Pubmedid: 15342383.

  • Hobbs JA, Cho S, Roberts TJ, Sriram V, Zhang J, Xu M, Brutkiewicz RR. Selective loss of natural killer T cells by apoptosis following infection with lymphocytic choriomeningitis virus. J Virol. 2001 Nov;75(22):10746-10754. Pubmedid: 11602716. Pmcid: PMC114656.

  • Tsao JL, Zhang J, Salovaara R, Li ZH, J?rvinen HJ, Mecklin JP, Aaltonen LA, Shibata D. Tracing cell fates in human colorectal tumors from somatic microsatellite mutations: evidence of adenomas with stem cell architecture. Am J Pathol. 1998 Oct;153(4):1189-1200. Pubmedid: 9777950. Pmcid: PMC1853055.

  • Henderson-Jackson E, Sexton W, Zhang J, Hakam A, Petrovskyy VS, Bui MM, Chuang ST. Cystic prostatic ductal adenocarcinoma: an unusual presentation and cytological diagnosis. Ann Clin Lab Sci. 2012 Winter;42(1):81-88. Pubmedid: 22371914.

Dr. Jingsong Zhang is a genitourinary oncologist at Moffitt Cancer Center and an assistant professor of oncology and internal medicine at the University of South Florida College of Medicine.  His primary interest is in developing new treatments for prostate cancer.

As a member of the Moffitt experimental therapeutics program, Dr. Zhang is researching novel agents that might inhibit the repair pathway that allows cancer  cells to survive despite DNA damaging chemotherapy treatment.  He is a principal investigator in an American Society of Clinical Oncology grant to target DNA damage repair pathways in metastatic prostate cancer.

Dr. Zhang received his medical degree from Peking Union Medical College in China, followed by a Ph.D. in pathology from the University of Southern California.  He served as a post-doctoral research fellow at Children’s Hospital Los Angeles, before pursuing a residency in internal medicine at New York Downtown Hospital and fellowship in hematology/oncology at University of Michigan Comprehensive Cancer Center.

Dr. Zhang has been published in numerous medical journals and is board certified in both medical oncology and internal medicine.  He is fluent in English and Chinese.